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tions. Two separate linear regression models were created
and analyzed. RESULTS: The chosen predictor variables
identiﬁed 9%, 4%, and 5% of the variance in treatment
costs for epoetin and iron injections, respectively. Signif-
icant predictors (p < 0.05) common to both models in-
cluded demographics, treatment facility, albumin levels,
body mass index, presence of heart conditions, end stage
renal disease (ESRD) for 2–3 year, ESRD for greater than
3 years, hypertension, BUN, and skilled nursing facility
wage index. Females, whites, increased body mass index,
and treatment at skilled nursing facilities were associated
with higher treatment costs. However, the relationship of
certain laboratory tests showed opposing relationships
with the outcome variable. CONCLUSIONS: Through
this study we found further evidence to reinforce ﬁndings
from the literature that dialysis related treatment costs are
inﬂuenced by a wide variety of variables. However, the
relationships vary with respect to the treatment chosen.
Future research should focus on employing additional
factors, which may help increase the explanation of dial-
ysis related treatment costs.
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Several published studies have reported on the estimated
costs associated with overactive bladder (OAB)—a con-
dition characterized by the symptom of urinary urgency,
not necessarily accompanied by incontinence, and often
associated with urinary frequency and nocturia. Although
OAB has been ranked among the 10 most common
chronic conditions in the United States, no known pub-
lished research has rigorously analyzed a key cost com-
ponent—the number of medical visits associated with 
this condition. OBJECTIVES: This study was designed to
explore US national data sets to recover component esti-
mates of resource use (c.f., ofﬁce visits, emergency visits,
hospitalizations) associated with symptoms of OAB.
METHODS: We examined US national databases to esti-
mate the number of annual OAB-associated medical visits
among patients at least 18 years of age. Three datasets
were used and included the National Ambulatory
Medical Care Survey (NAMCS), National Hospital
Ambulatory Medical Care Survey (NHAMCS), and the
National Hospital Discharge Survey (NHDS). Design
based statistical analyses were used to fully account for
the complex survey designs. Diagnostic codes identifying
patients with OAB symptomatology included ICD-9-CM
788.31, 788.41, and 788.33. RESULTS: During year
2000, there were an estimated 1.4 million (95% CI:
1.1–1.8 million) US ambulatory visits, with symptoms
characteristic of OAB, made to nonfederal ofﬁce-based
physicians. Even accounting for ER and outpatient
department visits as well as nonfederal short-stay hospi-
tal discharges, the estimated number of medical visits
with OAB-associated symptoms was less than 1.5 million.
CONCLUSIONS: Based on data derived from the
NOBLE program, a telephone and postal survey designed
to evaluate the prevalence of OAB, there are as many as
34 million adult Americans with OAB. Thus, conserva-
tively assuming one annual medical encounter per patient,
as few as 4% of these individuals sought medical treat-
ment during the year 2000. These statistics, therefore,
suggest a large unmet medical need.
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OBJECTIVE: Renal insufﬁciency, a chronic condition,
can adversely affect workforce productivity and increase
the economic burden on employers. This analysis quan-
tiﬁes the incremental direct (medical, drugs) and indirect
(absenteeism, disability) costs of NDRI from an
employer’s perspective. METHODS: Based on eligibility,
medical, pharmacy and disability claims data from 7 large
US employers covering January 1, 1998 through June 30,
2001, 1278 NDRI patients with at least 2 claims carry-
ing a renal insufﬁciency (RI) ICD-9 diagnosis code less
than 90 days apart were identiﬁed. These patients were
observed from the month of the ﬁrst RI diagnosis to the
month preceding the ﬁrst renal dialysis claim. A 10%
random sample of 154,171 individuals without NDRI
was selected as controls. Employer costs were measured
based on direct medical costs and employee productivity
loss. A tobit regression, which corrects for non-normality
of costs, included controls for age, gender, health plan,
location, diabetes, heart failure, any transplantation, and
liver cirrhosis. RESULTS: The unadjusted ratio of mean
direct and indirect costs for NDRI patients compared to
non-NDRI patients was 17.73 :1 ($1779.90 vs. $100.37
per patient-month, p < .01) and 5.91 :1 ($583.16 vs.
$98.74 per patient-month, p < .01), respectively. After
controlling for confounding factors, the ratios were 
5.50 :1 (95% CI: 5.47–5.53) for direct costs, and 2.10 :1
(95% CI: 2.02–2.17) for indirect costs. Regressions on
sub-categories yielded costs ratios for inpatient care, out-
patient care, prescription drugs, absenteeism, and dis-
ability (short and long-term) of 5.29 :1 (95% CI:
5.23–5.35), 4.05 :1 (95% CI: 4.01–4.08), 3.57 :1 (95%
CI: 3.55–3.59), 1.96 :1 (95% CI: 1.80–2.12), and 1.79 :
1 (95% CI: 1.75–1.83), respectively. CONCLUSION:
Both the unadjusted and adjusted cost ratios for NDRI
